Form 4: Quest Diagnostics CEO James E. Davis Sells 10,000 Shares

Quest Diagnostics CEO James E. Davis sold 10,000 shares of common stock on June 1, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• CEO and President James E. Davis sold 10,000 shares of Quest Diagnostics (DGX) common stock.
• The transaction occurred on June 1, 2026, at an average price of $194.14 per share.
• Following the sale, the reporting person retains beneficial ownership of 132,423 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks to avoid concerns about insider trading.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard practice for executive financial planning.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, indicating the sale was scheduled in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the CEO's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future stock performance, though 10b5-1 plans are standard practice for liquidity.

Future Outlook

No forward-looking guidance was provided in this filing.

Management Comments

• The filing notes that the sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are routine corporate governance events and generally do not signal a change in company strategy or operational health.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at major healthcare firms like LabCorp or HCA Healthcare to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the CEO's total holdings.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, James E. Davis, Stock Sale